Derek DiRocco

Derek DiRocco has worked in a variety of roles in the healthcare industry since 2013. Derek began their career at RA Capital Management, L.P. as an Analyst, Associate, Principal, and Partner. In 2018, they became a Director at 89bio. In 2019, they were appointed a Director at Frontier Medicines and a Board Observer at Peloton Therapeutics. In 2020, they became a Director at iTeos Therapeutics SA and a Board Observer at Vaxcyte. In 2021, they were appointed a Director at Acrivon Therapeutics, Inc. and Werewolf Therapeutics. In 2022, they became a Director at Mineralys Therapeutics, Inc. and Rivus Pharmaceuticals.

Derek DiRocco received their B.A. in Biology from College of the Holy Cross between 1998 and 2002. Derek then went on to pursue a PhD in Pharmacology from the University of Washington - School of Medicine, which they completed in 2009.